A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Saul MerinItay Chowers

Abstract

The aim of this study was to assess the neuroprotective effect of a topical alpha2-agonist in patients with retinal dystrophies. This study was a prospective, placebo-controlled, double-masked, randomized clinical trial. A total of 26 patients with retinal dystrophies were included. One (1) randomly selected eye was treated with brimonidine tartrate 0.2% twice-daily, while the fellow eye received artificial tears. Disease progression parameters tested at 6-8-month intervals throughout the study included Goldmann visual fields, contrast sensitivity, color vision, and fullfield electroretinography. Seventeen (17) of the 26 recruited patients completed the study. Except for 1 patient with an 18-month follow-up, all patients were followed up for 24-36 months (mean, 29). At the conclusion of the study, there were no differences detected in visual acuity, color vision, and contrast sensitivity between the treated and control eyes. There was a trend, however, toward a lesser degree of visual field loss in the brimonidine-treated eyes. There was also a delay in the time required to reach a 25% visual field loss in the treated eyes. These differences were more pronounced in a subgroup of patients diagnosed as retinitis pigmentosa and wi...Continue Reading

References

Oct 1, 1989·Archives of Ophthalmology·G A FishmanL M Jampol
Dec 1, 1982·The British Journal of Ophthalmology·S BisharaR J Deckelbaum
Jun 1, 1993·Archives of Ophthalmology·E L BersonW Willett
Nov 1, 1996·Survey of Ophthalmology·J Burke, M Schwartz
Feb 20, 1999·Survey of Ophthalmology·S van SoestA A Bergen
Apr 12, 2001·Ophthalmology·A R KentD Fellows
May 30, 2001·Survey of Ophthalmology·L A WheelerE WoldeMussie
Oct 11, 2001·European Journal of Ophthalmology·L A Wheeler, E Woldemussie
Mar 20, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Andrew A AcheampongDiane Tang-Liu
Jul 11, 2003·Survey of Ophthalmology·Larry WheelerRonald Lai
Mar 20, 2004·The British Journal of Ophthalmology·S S DandekarA J Hardcastle
Dec 22, 2004·Progress in Retinal and Eye Research·Andreas WenzelCharlotte E Remé
Feb 3, 2005·British Medical Bulletin·Daqing MaMervyn Maze
Mar 24, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Joseph R FerenczEhud I Assia
Sep 10, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Barbara WilhelmUNKNOWN BRAION Study Group
Sep 28, 2005·Investigative Ophthalmology & Visual Science·Sergio Mayor-TorroglosaManuel Vidal-Sanz
Oct 18, 2005·Ophthalmology·Sami Al-ShahwanDeepak P Edward
Nov 23, 2006·Experimental Eye Research·Nataliya O DanylkovaLinda K McLoon
Jan 2, 2007·Investigative Ophthalmology & Visual Science·Márta JanákyGyörgy Benedek

❮ Previous
Next ❯

Citations

Mar 12, 2009·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Elena ProkofyevaEberhart Zrenner
Dec 1, 2012·Ophthalmology and Therapy·P Mahesh ShanmugamManish Saxena
Jun 10, 2010·Korean Journal of Ophthalmology : KJO·Jung Hyun ParkHyeong Gon Yu
Dec 9, 2020·Cells·Yue RuanAdrian Gericke
Mar 21, 2021·The British Journal of Ophthalmology·Thales Antonio Cabral de GuimaraesMichel Michaelides

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.